The to a solo collaboration? A corporate partner brings the benefit of providing additional capital, resources and other materials to develop the ABX-EGF drug program, while limiting the level of risk taken by Abgenix. For example, the drug may not develop properly and fail in one or more leads, or possibly prove unsuccessful, this after Abgenix has provided a large portion of its limited resources. It is also an advantage if the partner has complementary knowledge, assets and resources to market, sell, test and develop the drug for marketing and/or testing purposes. A significant hurdle is the FDA's Center for Drug Evaluation and Research (CDER) testing phases and other regulations. When the drug demonstrates its effects and the company moves forward or makes the required changes, it develops the experience and knowledge that will be necessary for future drug compounds. A patchwork of studies has further shown that collaboration can be a powerful tool towards better results and increased productivity, since collective efficacy can significantly boost aspirations, motivational investment, morale and resilience of groups facing to challenges. It should be noted that there is competition in the market (AstraZeneca and Genetech), which manufacture similar products or are in the development phase copying techniques to fight cancer. That being said, the addition of a partner further helps Abgenix accelerate the commercialization of ABX-EGF, reducing various costs of adapting to sudden changes. Overall, it is in the best interest of Abgenix to partner with a partner to increase the opportunities the paper business is focused on. Both decisions involve resolving short-term cash flow needs and other resources. , which will reduce, whatever the choice, the commitment of one's personal assets and will free up time to concentrate on other prospects or areas of the business. Later, Abgenix will have to access or develop the areas it lacks. , such as the process of regulating, marketing and selling/supplying medicines to the market. To acquire these processes, or adapt more quickly, the joint venture would allow it to access the new capabilities of the company with which it is partnering. On the other hand, licensing the drug to another company does not have as many advantages. However, concerns about partnering with a company may lead to the exploitation or copying/removal of something proprietary, skill, technique or technology, which would harm future long-term gains...